// App-Quantinova.ai

TCT-750 : Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Researchers

Presenter

  • Andreas Baumbach

Principal Investigators

  • Harold Dauerman

  • Bernardo Cortese

  • Martial Hamon

  • Jayne Prats

  • Efthymios Deliargyris

  • Roxana Mehran

  • Gregg Stone

Medical Centers

  • Fatebenefratelli Hospital, Roma, Italy

  • University Hospital of CAEN, Caen, France

  • Bristol Heart Institute, Bristol, United Kingdom

  • Cardiovascular Research Institute, Burlington, VT

  • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Locations

  • France

  • United States

  • United Kingdom

  • Italy

Companies

  • The Medicines Compan

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Thrombocytopenia

  • Venous thrombosis

Biomarkers

  • Aspartate aminotransferase

Drug/Treatment

  • Heparin

  • Bivalirudin

  • Clopidogrel bisulfate

  • Prasugrel

  • Aspirin

  • Albyl-E

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved